PA
CRNX icon

Perceptive Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Perceptive Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-184,525
Closed -$9.43M – 92
2024
Q4 		$9.43M Sell
184,525
-540,173
-75% -$30.2M 0.26% 62
2024
Q3 		$37M Sell
724,698
-751,505
-51% -$38.8M 0.78% 35
2024
Q2 		$66.1M Hold
1,476,203
– – 1.59% 16
2024
Q1 		$69.1M Buy
1,476,203
+220,691
+18% +$8.64M 1.21% 28
2023
Q4 		$44.7M Sell
1,255,512
-8,220
-0.7% -$252K 1% 32
2023
Q3 		$37.6M Sell
1,263,732
-683,205
-35% -$14.1M 1.25% 25
2023
Q2 		$35.1M Sell
1,946,937
-1,607,950
-45% -$32.1M 1.02% 32
2023
Q1 		$57.1M Sell
3,554,887
-484,389
-12% -$8.96M 1.69% 17
2022
Q4 		$73.9M Sell
4,039,276
-1,281,756
-24% -$22.6M 2.08% 16
2022
Q3 		$105M Hold
5,321,032
– – 3.03% 9
2022
Q2 		$99.2M Buy
5,321,032
+157,515
+3% +$3.14M 3.11% 7
2022
Q1 		$113M Hold
5,163,517
– – 2.27% 11
2021
Q4 		$147M Buy
5,163,517
+1,200,000
+30% +$29.6M 2.26% 11
2021
Q3 		$83.4M Hold
3,963,517
– – 1.21% 22
2021
Q2 		$74.7M Buy
3,963,517
+304,136
+8% +$5.34M 0.97% 29
2021
Q1 		$51.6M Hold
3,659,381
– – 0.65% 43
2020
Q4 		$51.6M Hold
3,659,381
– – 0.55% 45
2020
Q3 		$57.3M Hold
3,659,381
– – 0.84% 34
2020
Q2 		$59.2M Buy
3,659,381
+1,071,428
+41% +$18.3M 0.96% 26
2020
Q1 		$38M Hold
2,587,953
– – 0.99% 23
2019
Q4 		$64.9M Hold
2,587,953
– – 1.29% 18
2019
Q3 		$38.9M Hold
2,587,953
– – 1.05% 26
2019
Q2 		$64.7M Hold
2,587,953
– – 1.48% 16
2019
Q1 		$58.9M Hold
2,587,953
– – 1.66% 18
2018
Q4 		$77.6M Hold
2,587,953
– – 2.95% 7
2018
Q3 		$74.1M Buy
+2,587,953
New +$76.8M 1.98% 11

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors's CRNX Position: Q1 2025 in Review

Perceptive Advisors sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2025, closing a stake of 184,525 shares — an estimated $9.43M sold.

Perceptive Advisors first reported a position in CRNX in Q3 2018 and held it in 26 quarters. The position peaked at $147M in Q4 2021. 227 funds tracked by Wall St. Rank hold CRNX as of Q1 2025.

  • Perceptive Advisors reported no remaining Crinetics Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Perceptive Advisors sold 184,525 Crinetics Pharmaceuticals shares in Q1 2025, an estimated $9.43M.
  • Perceptive Advisors first reported a position in Crinetics Pharmaceuticals in Q3 2018 and held it in 26 quarters.
  • Perceptive Advisors's Crinetics Pharmaceuticals position peaked at $147M in Q4 2021.
  • 227 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2025.

Based on Perceptive Advisors's 13F filing for Q1 2025, filed 15 May 2025.